Regenxbio (RGNX) Gross Margin (2014 - 2024)

Regenxbio's Gross Margin history runs 12 years deep, the most recent figure standing at 78.16% for Q4 2025.

• In Q4 2025, Gross Margin rose 795.0% year-over-year to 78.16%; the TTM figure through Dec 2025 stood at 87.72% (up 2836.0% YoY), while the FY2025 annual figure was 87.01%, up 2729.0% from the prior year.
• Gross Margin for Q4 2025 stood at 78.16%, down from 80.75% in the prior quarter.
• The five-year high for Gross Margin was 96.05% in Q1 2025, with the low at 29.26% in Q1 2022.
• The 5-year median for Gross Margin is 59.78% (2022), against an average of 64.42%.
• The sharpest annual moves came in 2022 and 2023: Gross Margin tumbled 4505 bps in 2022, then soared 4925 bps in 2023.
• Regenxbio's Gross Margin stood at 94.22% in 2021, then plunged by 37 bps to 59.22% in 2022, then fell by 17 bps to 49.41% in 2023, then jumped by 42 bps to 70.22% in 2024, then increased by 11 bps to 78.16% in 2025.
• Business Quant data shows RGNX's Gross Margin at 78.16% in Q4 2025, 80.75% in Q3 2025, and 75.61% in Q2 2025.